Sign In
Buy ATRC
$37.76
-2.39 (-5.95%)
At Close: Jul 31, 2026
AtriCure, Inc.'s (ATRC) CEO Mike Carrel on Q1 2021 Results - Earnings Call Transcript
11:22pm, Tuesday, 27'th Apr 2021
AtriCure, Inc.'s (ATRC) CEO Mike Carrel on Q1 2021 Results - Earnings Call Transcript
AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates
06:02pm, Tuesday, 27'th Apr 2021
AtriCure (ATRC) delivered earnings and revenue surprises of 7.32% and 5.39%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
AtriCure: Q1 Earnings Insights
04:37pm, Tuesday, 27'th Apr 2021
Shares of AtriCure (NASDAQ:ATRC) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 11.11% year over year to ($0.32), which beat t
Preview: AtriCure's Earnings
10:37am, Monday, 26'th Apr 2021
AtriCure (NASDAQ:ATRC) announces its next round of earnings this Tuesday, April 27. Here is Benzinga's everything-that-matters guide for this Tuesday's Q1 earnings announcement.
AtriCure, Inc. (ATRC) CEO Mike Carrel on Q4 2020 Results - Earnings Call Transcript
10:46pm, Tuesday, 23'rd Feb 2021
AtriCure, Inc. (ATRC) CEO Mike Carrel on Q4 2020 Results - Earnings Call Transcript
AtriCure to Announce Fourth Quarter and Full Year 2020 Financial Results
08:00am, Tuesday, 02'nd Feb 2021
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will r
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2020
07:00am, Monday, 11'th Jan 2021
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced preliminary financia
AtriCure (ATRC) Looks Good: Stock Adds 5.1% in Session
09:47am, Monday, 21'st Dec 2020
AtriCure (ATRC) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
AtriCure to Participate in the 39th Annual J.P. Morgan Healthcare Conference
08:00am, Monday, 14'th Dec 2020
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that
AtriCure, Inc. (ATRC) CEO Mike Carrel on Q3 2020 Results - Earnings Call Transcript
09:52pm, Sunday, 08'th Nov 2020
AtriCure, Inc. (ATRC) CEO Mike Carrel on Q3 2020 Results - Earnings Call Transcript
AtriCure to Participate in Upcoming Investor Conferences
08:00am, Monday, 26'th Oct 2020
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that
AtriCure to Announce Third Quarter 2020 Financial Results
12:00am, Tuesday, 13'th Oct 2020
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today anno
AQR Capital Management LLC Invests $705,000 in AtriCure Inc. (NASDAQ:ATRC)
07:46am, Friday, 02'nd Oct 2020
AQR Capital Management LLC acquired a new position in AtriCure Inc. (NASDAQ:ATRC) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commis
AtriCure (NASDAQ:ATRC) Shares Gap Down to $40.02
06:50am, Friday, 02'nd Oct 2020
Shares of AtriCure Inc. (NASDAQ:ATRC) gapped down before the market opened on Wednesday . The stock had previously closed at $40.02, but opened at $36.41. AtriCure shares last traded at $36.11, with a
AtriCure, Inc.: Surgical Device Maker's Growth Engines Face Fatal Complications (NASDAQ:ATRC)
01:30pm, Wednesday, 30'th Sep 2020
AtriCure's Convergent procedure, on which its hopes for growth are pinned, is unlikely to gain traction given a poor safety profile and lack of incremental efficacy relative to catheter-based procedur
